Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 3/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.34 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.34 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14338094 | 0.80 | NPSR1 (0.40) | NPSR1GAALMNAHTTKDM4E | |
| SCHEMBL13059464 | 0.71 | CYP11B1 (0.33) | CYP11B1CYP11B2NPSR1CACNA1FCACNA1D | |
| SCHEMBL13619706 | 0.70 | MAPK1 (0.45) | CYP11B1CYP11B2NPSR1GAALMNA | |
| SCHEMBL3756458 | 0.70 | CYP11B1 (0.41) | CYP11B1CYP11B2GAANAMPTCACNA1F | |
| SCHEMBL3761977 | 0.69 | GPR35 (0.35) | CYP11B1CYP11B2NPSR1CACNA1FCACNA1D | |
| SCHEMBL11617641 | 0.66 | KDM4E (0.51) | CYP11B1CYP11B2NPSR1KDM4EHPGD | |
| SCHEMBL11649033 | 0.66 | LMNA (0.43) | CYP11B1CYP11B2LMNAKDM4EHPGD | |
| SCHEMBL11617645 | 0.64 | CYP11B1 (0.39) | CYP11B1CYP11B2GAALMNAHTT | |
| SCHEMBL29225360 | 0.62 | LMNA (0.40) | NPSR1LMNAHTTKDM4EHPGD | |
| SCHEMBL25392428 | 0.62 | CYP11B1 (0.47) | CYP11B1CYP11B2LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038286-B1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2038286-B1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-7842838-B2 | Pyrro[1,2-b]pyridazinone intermediates | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842838-B2 | Pyrro[1,2-b]pyridazinone intermediates | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842838-B2 | Pyrro[1,2-b]pyridazinone intermediates | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| US-7582754-B2 | For treating hepatitis C virus infections; polymerase inhibitors | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582754-B2 | For treating hepatitis C virus infections; polymerase inhibitors | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090105473-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105473-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| EP-2038286-A1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | Anadys Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7462611-B2 | inhibitor of HCV NS5B polymerase; to treat infections caused by hepatitis C virus; 3-(1,1-Dioxo-1,4-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-4-hydroxy-1-(3-methyl-butyl)-pyrrolo[1,2-b]pyridazin-2-one | ANADYS PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462611-B2 | inhibitor of HCV NS5B polymerase; to treat infections caused by hepatitis C virus; 3-(1,1-Dioxo-1,4-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-4-hydroxy-1-(3-methyl-butyl)-pyrrolo[1,2-b]pyridazin-2-one | ANADYS PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462611-B2 | inhibitor of HCV NS5B polymerase; to treat infections caused by hepatitis C virus; 3-(1,1-Dioxo-1,4-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-4-hydroxy-1-(3-methyl-butyl)-pyrrolo[1,2-b]pyridazin-2-one | ANADYS PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080031852-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080031852-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080031852-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2007150001-A1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, CYP4B1, CYP1B1 | CYP11B1 42/4885CYP11B2 57/4885NPSR1 3266/4885 |
| US-20080031852-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, CYP4B1, CYP1B1 | CYP11B1 42/4885CYP11B2 57/4885NPSR1 3266/4885 |
| US-20090105473-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, CYP4B1, CYP1B1 | CYP11B1 42/4885CYP11B2 57/4885NPSR1 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.